Trial Profile
A Randomised Controlled Trial of the Efficacy and Safety of Alemtuzumab (MABCAMPATH) for Prevention of Graft Rejection and Preservation of Renal Function in Patients Receiving Kidney Transplants
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Azathioprine; Corticosteroids; Methylprednisolone; Tacrolimus
- Indications Renal transplant rejection
- Focus Adverse reactions
- Acronyms CAMP-ASIA2
- 16 Aug 2011 New trial record